Back to dashboard
All PlansCoverageMedium impact

Oncologic Applications of Photodynamic Therapy, Including Barrett Esophagus

Blue Cross & Blue Shield of Mississippi·MS · Oncology, Gastroenterology, Pulmonology +1 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This policy establishes coverage guidelines for photodynamic therapy (PDT) in oncologic applications, specifying that it is medically necessary for palliative treatment of obstructing esophageal cancer, obstructing endobronchial lesions, early-stage NSCLC in non-surgical candidates, high-grade dysplasia in Barrett esophagus, and unresectable cholangiocarcinoma with stenting. Other oncologic applications remain investigational and non-covered.

Action Required

Action needed
Immediately: Billing team must review current PDT claims to ensure they align with covered indications (obstructing esophageal cancer, endobronchial lesions, early-stage NSCLC in non-surgical patients, high-grade Barrett esophagus dysplasia, and unresectable cholangiocarcinoma with stenting). Update billing guidelines to flag PDT claims for other oncologic applications as investigational/non-covered. Verify proper documentation of medical necessity criteria before submitting PDT claims.

Related policy hubs